# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Theodore Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI012-SYN
- Date: 2026-06-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Amos Kettering, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month asthma review with repeat spirometry. **S**

## History of present illness

Mr. Roosevelt returns three months after starting maintenance-and-reliever therapy. Since the four-week review he has had no night waking and daytime symptoms about once a week. He uses one as-needed inhalation before training and rarely any other. He has not missed an evening dose since setting a reminder. The bedding covers are in place. His home peak flow has settled between 590 and 610 L/min, so 610 is his personal best. He is back to full boxing, rowing, and a long hill walk most weekends. No exacerbations, urgent visits, or oral corticosteroids. **S**

| Element | Detail |
|---|---|
| Interval change | No night waking; symptoms about once a week |
| Reliever use | One inhalation before training; rarely otherwise |
| Adherence | All maintenance doses taken since setting a reminder |
| Home peak flow | 590 to 610 L/min; personal best 610 |
| Function | Full training |
| Exacerbations | None since starting controller therapy |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No night cough or wheeze; breathless only at the end of hard rowing pieces |
| Ears, nose, mouth, and throat | Negative | No hoarseness or sore mouth |
| Musculoskeletal | Negative | No injuries from training |

3 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenance **S**
- Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in total **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73 kg; BMI 23.8 kg/m². All vital signs are synthetic.

FEV1: 3.98 L; FEV1 percent predicted: 89%; FVC: 5.02 L; FEV1/FVC ratio: 0.79; Peak expiratory flow: 605 L/min; Asthma Control Test: 22. All results are synthetic.

## Change since baseline

- FEV1 percent predicted: 72% (low) at baseline, 89% at this visit **S**
- FVC: 4.8 L at baseline, 5.02 L at this visit **S**
- FEV1/FVC ratio: 0.67 (low) at baseline, 0.79 at this visit **S**
- Asthma Control Test: 13 at baseline, 22 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Mouth | No thrush |
| Lungs | Clear, with no wheeze on forced expiration |
| Inhaler technique | Correct with his own inhaler and spacer |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Moderate persistent asthma, well controlled** (J45.40). Asthma Control Test 22. Spirometry has normalized: FEV1 3.98 L (89 percent predicted) and FEV1/FVC 0.79, up from 3.20 L and 0.67 at intake. Peak flow 605 L/min today. He has been well controlled for about two months. **S**
   - Continue budesonide-formoterol two inhalations twice daily and one as needed.
   - Action plan reset to his personal best of 610 L/min: green 488 or above, yellow 305 to 487, red below 305.
   - Consider stepping down at the six-month review if control holds and there are no exacerbations.
   - Next spirometry in one to two years unless control changes.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 22, well controlled |
| Examination | Spirometry | At diagnosis, 3 to 6 months after stabilization, then every 1 to 2 years | Completed today | FEV1 3.98 L, 89 percent predicted; FEV1/FVC 0.79; FVC 5.02 L |
| Examination | Peak flow and personal best | Daily or with symptoms for moderate to severe asthma | Completed today | 605 L/min in clinic; personal best 610 L/min |
| Examination | Inhaler technique with his own device | Every visit | Completed today | Correct |
| Medication safety | Adherence and reliever use | Every visit | Completed today | Full adherence; reliever before training only |
| Survey | Exacerbation history | Every visit | Completed today | None since starting controller therapy |
| Self-management | Trigger and exposure review, smoking and vaping status | Every visit | Completed today | Bedding covers in place; never smoker |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Zones reset to the confirmed personal best |
| Survey | Step-up or step-down assessment | Every visit | Completed today | Controlled for about two months; reassess for step-down at the six-month review |
| Laboratory | FeNO and blood eosinophils | As indicated | Not indicated | Phenotyping completed at the four-week review; no diagnostic uncertainty |
| Referral | Biologic candidacy assessment | Only if severe and uncontrolled despite optimized Step 4 to 5 therapy | Not indicated | Well controlled at Step 4 |
| Medication safety | Vaccination status | Yearly | Up to date | PCV20 given at the four-week review; influenza vaccine due in the autumn |

## Goal progress

- Asthma Control Test score of 20 or more by the three-month review. Outcome by 2026-06-08: ACT rose from 13 to 22. **S**
- FEV1 of 80 percent predicted or more on spirometry after stabilization. Outcome by 2026-06-08: FEV1 89 percent predicted with a normal FEV1/FVC ratio. **S**
- No exacerbation needing oral corticosteroids over the six months after starting controller therapy. In progress; target 2026-09-14. **S**
- Return to full boxing and rowing training without limiting symptoms. Outcome by 2026-06-08: Training fully by the three-month review, using one reliever inhalation before sessions. **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026), Aether Forge

## Follow-up

- Asthma review in three months, or within one week of any exacerbation. **S**
- Next scheduled visit 2026-09-14: six-month asthma review after a summer exacerbation. **S**
